EU regulators have launched an “optimized” version of their popular pilot program that allows drug developers to seek national scientific advice simultaneously from two EU member states on specific scientific, technical or regulatory issues.
The second phase of the Simultaneous National Scientific Advice (SNSA) pilot incorporates an “an optimised procedure intended to maximise the benefits for both applicants and competent authorities,” according to a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?